NCT06155500: Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

Study Summary

CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.

Want to learn more about this trial?

Request More Info

Interventions

OTQ923BIOLOGICAL

There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907)

Study Locations

Facility	City	State	Country
University of Chicago	Chicago	Illinois	United States
Memorial Sloan Kettering Cancer Ctr	New York	New York	United States
St Jude Childrens Research Hospital	Memphis	Tennessee	United States

Official Trial Information

View on ClinicalTrials.gov